CTRI/2020/12/029783招募中未知
Therapy with nintedanib â??Does it improve outcome in patients of Covid-19 pneumonia if given early?
试验速览
- 阶段
- 未知
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •All cases of covid 19 pneumonia detected as COVID positive within <= 30 days or with history and CT suggestive of covid 19 .
- •CT-severity score >=15 and CORADS-4/5/6
排除标准
- •-Patients having other interstitial lung diseases.
- •- Patient having CKD or creatinine clearance <30 and CLD with deranged LFT will be excluded.
- •-Not fulfilling the criteria for study
- •-Not giving consent for study.
研究者
相似试验
招募中
不适用
The safety and efficacy of nintedanib for patients with progressive fibrosing interstitial lung disease in a real world setting-a prospective observational studyProgressive fibrosing interstitial lung diseaseJPRN-UMIN000041380Department of Respiratory Medicine, Juntendo University Hospital300
进行中（未招募）
1 期
Efficacy of Nintedanib per os as a treatment for epistaxis in HHT diseaseEPICUREHereditary Hemorrhagic TelangiectasiaMedDRA version: 20.1Level: LLTClassification code 10019887Term: Hereditary hemorrhagic telangiectasiaSystem Organ Class: 100000004850EUCTR2019-002593-31-FRHospices Civils de Lyon60
招募中
不适用
Efficacy and safety of nintedanib for progressive fibrosing interstitial diseases in single center cohort studyJPRN-UMIN000042254Japanese Red Cross Medical Center40
尚未招募
3 期
intedanib the game changer in COVID 19 patientsCTRI/2021/07/035256Self
进行中（未招募）
1 期
iCCC - A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or EndometriumRecurrent clear cell carcinoma of the ovary or endometriumMedDRA version: 21.1Level: PTClassification code 10009252Term: Clear cell endometrial carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-002109-73-NLEuropean Organisation for Research and Treatment of Cancer120